Abstract. Myocardial infarction (MI) is a predominant and severe complication in patients that undergo aortocoronary bypass surgery. Angiotensin-converting enzyme 2 (ACE2) activation is reportedly a protective mechanism in MI; therefore, in the present study, the association between serum ACE2 levels and postoperative MI following coronary artery bypass grafting (CABG) was investigated. Preoperative and postoperative serum ACE2 levels in 136 subjects undergoing CABG were observed and the serum ACE2 levels, 1 h post surgery, were divided into quartile categories. Following adjustment for age, gender, body mass index, hypertension, previous MI, current smoking status, hyperlipidemia, diabetes mellitus, Gensini score, aortic clamp time, number of grafts and pre-CABG medications; the risk of developing postoperative MI following CABG was observed to be significantly higher in the lowest serum ACE2 level quartile than when compared with the highest quartile (hazard ratio, 2.94; 95% confidence interval, 1.85-4.16; P=0.009). The subjects that exhibited a serum ACE2 level ≤1.06 ng/ml showed significantly higher rates of postoperative MI, arrhythmia and reduced cardiac output in addition to increased instances of in-hospital mortality post CABG, compared with those exhibiting a serum ACE2 level >1.06 ng/ml. A significant negative correlation was observed between serum ACE2 and serum cardiac troponin I levels, however, no significant association was identified between the serum ACE2 level quartiles and the ACE2 gene polymorphisms. The present study indicated that a low serum ACE2 level, 1 h post CABG was independently associated with an increased risk of postoperative MI. Thus, the serum ACE2 level may be a potential novel prognostic factor for postoperative MI following CABG.

Introduction

Despite substantial advances in surgical, cardioprotective and anesthetic techniques, the incidence of myocardial infarction (MI) following cardiac surgery remains between 3 and 15% and is associated with reduced, long-term survival rates (1). Postoperative MI is a predominant and severe complication in patients undergoing aortocoronary bypass surgery and is a multifactorial disorder with significant inter-patient variability, which is poorly predicted by clinical procedures (1). The development of MI following cardiac surgery has been associated with high morbidity, mortality and cost (2).

The renin-angiotensin system (RAS) is crucial in cardiovascular regulation (3). In the RAS, angiotensin-converting enzyme (ACE) metabolizes angiotensin (Ang) I to form Ang II, which exerts a direct trophic effect upon cardiovascular cells (3). Local Ang II production is important in the pathophysiology of the RAS in the cardiovascular system (4) and recently, ACE2, a novel member of the RAS, was identified to function as a negative regulator of the Ang system by metabolizing Ang II in to a putatively protective peptide Ang (1-7) exhibiting high efficiency (5-7). ACE2 is present in the heart and a reduction in its expression is associated with enhanced cardiac hypertrophy and reduced pumping ability (8,9). Although ACE2 was initially localized exclusively in the cardiac endothelial cells, more recent studies have demonstrated ACE2 immunoreactivity in the endothelial and smooth muscle cells of the myocardial vessels, as well as within cardiomyocytes (8,9). Following MI, significant activation of cardiac ACE2 occurs in rats and humans, which combats the adverse effect of an activated cardiac RAS (8).

Further evidence of the cardioprotective role of ACE2 arises from studies conducted on ACE2-knockout mice, where the loss of ACE2 facilitated adverse, post-MI ventricular remodeling (10); furthermore, previous studies have indicated that ACE2 overexpression in MI rats improved cardiac contractility and remodeling (10,11). It has been identified that ACE2 serum activity increases during the first week following an acute MI.
and that ACE2 activation may be a compensatory mechanism in MI (12).

In the present study, the association between serum ACE2 levels and postoperative MI, following coronary artery bypass grafting (CABG), was investigated.

**Patients and methods**

**Patients.** Between March 2008 and April 2013, 136 Han Chinese patients, who underwent CABG with a cardiopulmonary bypass (CPB) at the Department of Cardiothoracic Surgery of the Second Xiangya Hospital, Central South University (Hunan, China) were enrolled in the present study. The exclusion criteria were a history of renal failure, active liver disease, bleeding disorders, autoimmune diseases or immunosuppressive therapy; patients with a family history of coronary artery disease were also excluded. The present study was approved by the Ethics Committee of the Second Xiangya Hospital, Central South University and the participants provided written informed consent prior to commencing the study.

**Definition of postoperative MI.** According to definitions for periprocedural necrosis and periprocedural infarction, collectively established by the American College of Cardiology Foundation, American Heart Association, European Society of Cardiology and the World Heart Federation taskforce, cardiac troponin I (cTnI) is the preferred biomarker for MI. Post-CABG biomarker values that exceed the 99th percentile of the normal reference range represent myocardial necrosis (13) and in the present study, a postoperative MI was defined as an increase of cTnI to greater than five times the 99th percentile of the normal reference range, during the first 72 h following CABG. This was in addition to manifestations of novel pathological Q-waves, a left bundle branch block, an angiographically documented novel graft of native coronary artery occlusion or imaging evidence of a novel loss of a viable MI (13).

**Data collection.** Patients that were undergoing CABG ceased all antiplatelet agent usage at least two days prior to surgery. Intraoperative anesthetic, perfusion and cardioprotective management was standardized, using fentanyl-isoflurane anesthesia, nonpulsatile CPB (32-35°C), crystalloid prime, pump flow rates >2.4 l/min/m², cold blood cardioplegia, α-stat blood gas management, heparin (to maintain activated clotting times >450 secs), e-aminoacapric acid infusion and serial hematocrit 1 h post surgery, were divided into quartile categories, ≤1.06, 1.07-1.42, 1.43-1.85 and ≥1.86 ng/ml (1). The serum ACE2 levels were measured in the serum ACE2 level for postoperative MI following CABG, the ACE2 level observed in the patients who underwent CABG surgery, and postoperative days 1, 2, 6, 9 and 12. The serum ACE2 level was analyzed 1 h post surgery; this was the earliest time point at which the serum ACE2 level began to rise 1 h post CABG; six days after surgery, the serum ACE2 levels peaked and subsequently returned to baseline 12 days post surgery (Fig. 1). To investigate the prognostic value of the serum ACE2 level for postoperative MI following CABG, the serum ACE2 level was analyzed 1 h post surgery; this was the earliest time point at which the serum ACE2 level began to rise above baseline following CABG. The serum ACE2 levels that were observed 1 h post surgery, were divided into quartile categories; ≤1.06, 1.07-1.42, 1.43-1.85 and ≥1.86 ng/ml. No statistically significant differences were identified between the quartile categories in age, gender, body mass index (BMI), current smoking status, unstable angina, prior MI and prevalence of hyperlipidemia, hypertension and diabetes mellitus.

**Statistical analysis.** Serum ACE2 levels were divided into quartile categories; ≤1.06, 1.07-1.42, 1.43-1.85 and ≥1.86 ng/ml. The adjusted hazard ratios (HRs) and the 95% confidence intervals (CIs) were calculated using the Cox proportional hazard model. The continuous variable values were expressed as the mean ± standard deviation and comparisons between the means of the two groups were performed using Student’s t-test. The categorical variables were expressed as n (%) and analyzed using the χ² test. Statistical analysis was performed using SPSS version 10.0 (SPSS Inc., Chicago, IL, USA). The statistical significance level of this study was set at a two-tailed α=0.05.

**Results**

**Serum ACE2.** The serum ACE2 levels were measured in the blood samples collected on preoperative days 3 and 1, 1 h post surgery, and postoperative days 1, 2, 6, 9 and 12. The serum ACE2 level observed in the patients who underwent CABG with CPB, was at baseline level prior to surgery and began to rise 1 h post CABG; six days after surgery, the serum ACE2 levels peaked and subsequently returned to baseline 12 days post surgery (Fig. 1). To investigate the prognostic value of the serum ACE2 level for postoperative MI following CABG, the serum ACE2 level was analyzed 1 h post surgery; this was the earliest time point at which the serum ACE2 level began to rise above baseline following CABG. The serum ACE2 levels that were observed 1 h post surgery, were divided into quartile categories; ≤1.06, 1.07-1.42, 1.43-1.85 and ≥1.86 ng/ml. No statistically significant differences were identified between the quartile categories in age, gender, body mass index (BMI), current smoking status, unstable angina, prior MI and prevalence of hyperlipidemia, hypertension and diabetes mellitus.

**Genotyping.** Three single nucleotide polymorphisms (SNPs), 1075A/G (rs1978124), 8790A/G (rs2285666) and 16854G/C (rs4646142) were selected as proxies to investi-
Furthermore, there were no statistically significant differences observed between the quartile categories regarding disease pattern, procedural characteristics and pre-CABG medication use (Table II).

**Table I. General characteristics of study subjects.**

| Serum ACE2 quartile categories, ng/ml (n=34) | \(\leq 1.06\) | 1.07-1.42 | 1.43-1.85 | \(\geq 1.86\) | P-value |
|--------------------------------------------|----------------|------------|------------|---------------|---------|
| Age (years)                                | 63.5±4.5       | 64.2±3.8   | 63.2±3.4   | 63.7±4.2      | 0.29    |
| Gender                                     |                |            |            |               | 0.83    |
| Male, n (%)                                | 27 (79.4)      | 29 (85.3)  | 26 (76.5)  | 27 (79.4)     |         |
| Female, n (%)                              | 7 (20.6)       | 5 (14.7)   | 8 (23.5)   | 7 (20.6)      |         |
| Unstable angina                            | 14 (41.2)      | 15 (44.1)  | 13 (38.2)  | 11 (32.4)     | 0.78    |
| Hyperlipidemia, n (%)                      | 31 (91.2)      | 31 (91.2)  | 32 (94.1)  | 30 (88.2)     | 0.87    |
| Hypertension, n (%)                        | 22 (64.7)      | 21 (61.8)  | 23 (67.6)  | 18 (52.9)     | 0.63    |
| Diabetes mellitus, n (%)                   | 6 (17.6)       | 5 (14.7)   | 7 (20.6)   | 5 (14.7)      | 0.90    |
| Prior MI                                    | 9 (26.5)       | 10 (29.4)  | 8 (23.5)   | 8 (23.5)      | 0.94    |
| BMI (kg/m\(^2\))                           | 28.7±4.8       | 27.9±6.0   | 29.3±5.2   | 28.1±4.9      | 0.27    |
| Current smoker                             | 8 (23.5)       | 12 (35.3)  | 9 (26.5)   | 11 (32.4)     | 0.70    |

ACE, angiotensin-converting enzyme; MI, myocardial infarction; BMI, body mass index.

**Table II. Disease and procedural characteristics of study subjects.**

| Serum ACE2 quartile categories, ng/ml (n=34) | \(\leq 1.06\) | 1.07-1.42 | 1.43-1.85 | \(\geq 1.86\) | P-value |
|--------------------------------------------|----------------|------------|------------|---------------|---------|
| Disease pattern                            |                |            |            |               |         |
| LM or LM+1 vessel, n (%)                   | 3 (8.8)        | 4 (11.8)   | 3 (8.8)    | 2 (5.9)       | 0.87    |
| LM+2 or 3 vessels, n (%)                   | 5 (14.7)       | 4 (11.8)   | 4 (11.8)   | 3 (8.8)       | 0.90    |
| Two vessel, n (%)                          | 8 (23.5)       | 9 (26.5)   | 8 (23.5)   | 6 (17.6)      | 0.85    |
| Three vessel, n (%)                        | 18 (52.9)      | 17 (50.0)  | 19 (55.9)  | 23 (67.6)     | 0.48    |
| Lesions (n)                                | 3.1±0.2        | 3.0±0.3    | 3.0±0.3    | 3.2±0.4       | 0.83    |
| Gensini score                              | 37.5±4.6       | 37.3±5.1   | 37.4±4.8   | 37.0±3.9      | 0.92    |
| Procedural characteristics                 |                |            |            |               |         |
| On-pump, n (%)                             | 34 (100.0)     | 34 (100.0) | 34 (100.0) | 34 (100.0)    | 1.00    |
| CPB time (mins)                            | 49.5±3.9       | 52.3±4.2   | 54.2±3.9   | 53.6±4.5      | 0.41    |
| Aortic clamp time (mins)                   | 32.5±1.9       | 31.9±2.0   | 33.2±2.1   | 32.9±2.7      | 0.53    |
| Grafts (n)                                 | 2.5±0.2        | 2.4±0.2    | 2.5±0.1    | 2.5±0.2       | 0.95    |
| LIMA use, n (%)                            | 30 (88.2)      | 31 (91.2)  | 31 (91.2)  | 30 (88.2)     | 0.96    |
| SVG use, n (%)                             | 30 (88.2)      | 31 (91.2)  | 31 (91.2)  | 30 (88.2)     | 0.96    |
| Free arterial graft use, n (%)             | 4 (11.8)       | 3 (8.8)    | 3 (8.8)    | 4 (11.8)      | 0.96    |

Continuous variable values were expressed as the mean ± standard deviation. ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; CABG, coronary artery bypass grafting; CPB, cardiopulmonary bypass; LIMA, left internal mammary graft; LM, left main; SVG, saphenous vein graft.

Postoperative MI increases following a decrease in the levels of serum ACE2. Postoperative MI increased as the serum ACE2 level decreased and the risk was identified to be significantly higher in the first quartile group when compared (Table I). Furthermore, there were no statistically significant differences observed between the quartile categories regarding disease pattern, procedural characteristics and pre-CABG medication use (Table II).
with the second, third and fourth quartile groups (Model 1; Table III). Following adjustment for age, gender, BMI, hypertension, prior MI, current smoking status, hyperlipidemia, diabetes mellitus, Gensini score, aortic clamp time, number of grafts and pre-coronary artery bypass grafting medications. HR, hazard ratio; MI, myocardial infarction; ACE2, angiotensin-converting enzyme 2; BMI, body mass index.

Table III. Adjusted HRs of postoperative MI by serum ACE2 levels.

| Serum ACE2 quartile categories, ng/ml (n=34) | P-value for trend (across categories) | Continuous log scalea | P-value for trend (continuous) |
|---------------------------------------------|---------------------------------------|-----------------------|--------------------------------|
| ≤1.06                                       | 1.07-1.42                             | 1.43-1.85             | ≥1.86                         |
| Postoperative MI                            |                                       |                       |                                |
| MI, n (%)                                   |                                       |                       |                                |
| ≤1.06                                       | 9 (26.5)                              | 5 (14.7)              | 4 (11.8)                       | 2 (5.9)                       |
| Model 1b HR                                 | 5.76                                  | 2.76                  | 2.13                           |                                |
| (95% CI)                                    | (1.14-29.08)                          | (0.50-15.33)          | (0.86-12.51)                   | (Reference)                   |
| Model 2c HR                                 | 2.94                                  | 1.49                  | 1.19                           |                                |
| (95% CI)                                    | (1.85-4.16)                           | (0.92-2.58)           | (0.57-2.11)                    | (Reference)                   |
| aHR per 1 - standard deviation decrease of log-transformed ACE2 levels; bModel 1: Adjusted for age, gender and BMI; cModel 2: Adjusted for age, gender, BMI, hypertension, prior MI, current smoking status, hyperlipidemia, diabetes mellitus, Gensini score, aortic clamp time, number of grafts and pre-CABG medications. HR, hazard ratio; MI, myocardial infarction; ACE2, angiotensin-converting enzyme 2; BMI, body mass index.

Table IV. ACE2 levels with postoperative morbidities and in-hospital mortality.

| Serum ACE2 quartile categories (ng/ml) | Total (n=136) | ≤1.06 (n=34) | >1.06 (n=102) | P-value |
|---------------------------------------|---------------|--------------|---------------|---------|
| Postoperative MI                       | 20 (14.7)     | 9 (26.5)     | 11 (10.8)     | 0.046*  |
| Arrhythmia                             | 37 (27.2)     | 14 (41.2)    | 23 (22.5)     | 0.045*  |
| Low cardiac output                     | 17 (12.5)     | 8 (23.5)     | 9 (8.8)       | 0.036*  |
| Pulmonary complications                | 21 (15.4)     | 8 (23.5)     | 13 (12.7)     | 0.170   |
| Neurologic complications               | 6 (4.4)       | 2 (5.9)      | 4 (3.9)       | 0.640   |
| Excessive bleeding                     | 3 (2.2)       | 1 (2.9)      | 2 (2.0)       | 1.000   |
| In-hospital mortality                  | 6 (4.4)       | 4 (11.8)     | 2 (2.0)       | 0.034*  |

*P<0.05. Data are expressed as n (%). ACE2, angiotensin-converting enzyme 2; MI, myocardial infarction.

ACE2 polymorphisms. ACE2 polymorphisms are reportedly associated with MI; Yang et al (14) reported that ACE2 SNPs, 1075A/G (rs1978124), 8790A/G (rs2285666) and 16854G/C (rs4646142) were associated with MI (14). Association analysis that was conducted with female subjects indicated that the 1075AA and 16854GG genotypes were significantly associated with MI (P<0.05) and that the 8790AA genotype was associated with MI at a non-significant level (P=0.058). In the male subjects, the 1075A/G-8790A/G and 16854G/C haplotype GGC was significantly associated with MI, when compared with the most common haplotype AAG (P<0.05) (14). To determine whether those ACE2 polymorphisms were associated with the serum ACE2 level in the present study, the association between the serum ACE2 level and the ACE2 genotypes and haplotypes, reportedly associ-
ated with MI, were examined in all of the subjects. As the ACE2 gene is located on the X chromosome, the association analysis was conducted by gender. There was no significant association observed between the serum ACE2 level quartile groups and the ACE2 1075AA, 16854GG or 8790AA genotypes in the female subjects, or the ACE2 1075A/G-8790A/G and 16854G/C haplotype GGC in the male subjects (Table V).

The results indicated that the observed association between the serum ACE2 level and postoperative MI following CABG, in the present study, was not a result of ACE2 gene polymorphisms.

**Table V. ACE2 polymorphisms and serum ACE2 levels.**

| ACE2 polymorphisms          | Serum ACE2 quartile categories (ng/ml) | ≤1.06 | 1.07-1.42 | 1.43-1.85 | ≥1.86 | Total | P-value |
|-----------------------------|----------------------------------------|-------|-----------|-----------|-------|-------|---------|
| 1075A/G (rs1978124)         | AA                                     | 3     | 2         | 2         | 2     | 9     | 0.87    |
|                             | Non-AA                                 | 4     | 3         | 6         | 5     | 18    |         |
|                             | Total                                  | 7     | 5         | 8         | 7     | 27    |         |
| 8790A/G (rs2285666)         | AA                                     | 2     | 1         | 3         | 3     | 9     | 0.85    |
|                             | Non-AA                                 | 5     | 4         | 5         | 4     | 18    |         |
|                             | Total                                  | 7     | 5         | 8         | 7     | 27    |         |
| 16854G/C (rs4646142)        | GG                                     | 3     | 3         | 4         | 2     | 12    | 0.73    |
|                             | Non-GG                                 | 4     | 2         | 4         | 5     | 15    |         |
|                             | Total                                  | 7     | 5         | 8         | 7     | 27    |         |

| ACE2 polymorphisms          | Serum ACE2 quartile categories (ng/ml) | ≤1.06 | 1.07-1.42 | 1.43-1.85 | ≥1.86 | Total | P-value |
|-----------------------------|----------------------------------------|-------|-----------|-----------|-------|-------|---------|
| 1075A/G-8790A/G and 16854G/C haplotype | GGC   | 3     | 7         | 4         | 6     | 20    | 0.57    |
|                             | Non-GGC                                | 24    | 22        | 22        | 21    | 89    |         |
|                             | Total                                  | 27    | 29        | 26        | 27    | 109   |         |

ACE, angiotensin-converting enzyme.

**Discussion**

MI is a predominant and severe complication in patients undergoing aortocoronary bypass surgery. Early diagnosis and prediction of MI is an important condition for optimal postoperative patient management. Previous studies have indicated that ACE2 activation is a protective mechanism in MI and that supplementing ACE2 may be a potential therapy for MI/ischemic heart disease (8-11,15). In the present study, the results indicated that the serum ACE2 level was associated with postoperative MI and in-hospital mortality following CABG.

The serum ACE2 level remained at baseline level preoperatively, began to rise 1 h post CABG, peaked on day 6 post surgery and returned to baseline level on day 12, post surgery. As MI can occur within 24 h of CABG, the serum ACE2 level 1 h post surgery was analyzed to evaluate the potential prognostic value of the serum ACE2 level for postoperative MI following CABG. The association analysis results 1 h post surgery were significant compared with those at other time points. According to previous studies, the duration of aortic cross-clamping, number of coronary grafts and history of previous cardiac surgery were independent predictors of postoperative MI (1). In addition, ACE inhibitors and angiotensin receptor blockers are capable of enhancing ACE2 expression (16,17). Thus, the hazard ratio was adjusted for prior MI, aortic clamp time, number of grafts and pre-CABG medications, in addition to a variety of other confounding factors that may have affected the incidence of postoperative MI and/or serum ACE2 levels, including age, gender, BMI, hypertension, current smoking status, hyperlipidemia, diabetes mellitus and Gensini score. After adjusting for the confounding factors, the risk of developing postoperative MI remained significantly higher in the lowest serum ACE2 level quartile group than in the highest quartile group, 1 h post surgery, indicating that the
serum ACE2 level 1 h post surgery may be an independent risk factor for postoperative MI following CABG. Thus, the serum ACE2 level 1 h post surgery may be a potential novel biomarker or prognostic factor for postoperative MI following CABG; its value in clinical applications may be investigated in future studies using a larger patient population.

Postoperative MI, following cardiac surgery is associated with reduced long-term survival rates (1). In the present study, the serum ACE2 level in the lowest quartile group was observed to be associated with the increased rate of postoperative MI, arrhythmia, low cardiac output and in-hospital mortality, indicating that the serum ACE2 level may be a potential novel prognostic factor for short-term survival following cardiac surgery. A prospective study, using the same patient cohort, is being conducted to investigate the association between the serum ACE2 level, postoperative MI and long-term survival rate following CABG.

cTnl, a contractile protein unique to the heart muscle, is a sensitive biomarker, which was introduced predominantly for risk stratification in patients exhibiting acute coronary syndrome and is the gold standard for identifying MI (18,19); in addition, ACE2 is expressed in the heart and has been observed to exhibit a protective effect during MI (8-11). Increasing evidence indicates that the expression of cardiac ACE2 is higher following MI, which combats the adverse effects of an activated cardiac RAS and, therefore, may be a compensatory mechanism in MI (8-11,15,20). In agreement with this, a significant increase in the ACE2 serum level following MI was observed in the present study. Notably, postoperative serum ACE2 and cTnl levels exhibited significant negative correlation, which confirmed that ACE2 protects against MI; therefore, a relatively low serum ACE2 level shortly after CABG, may indicate a deficient protective mechanism against MI. This may explain why the risk of developing postoperative MI was significantly greater in the lowest serum ACE2 level quartile group following CABG. The troponin system has been observed to be extremely sensitive, however, not definitive (21). Therefore, future investigations are required to identify whether the serum ACE2 level may be a more specific marker than cardiac troponin levels for detecting postoperative MI.

Polymorphisms in the ACE2 gene are associated with the development of pathological myocardial hypertrophy and heart disease in humans (14). No significant associations were identified between the serum ACE2 level quartile groups and the ACE2 genotypes and haplotypes, in the present study, which were identified to be associated with MI in previous studies (14). Although the sample size may not be adequate for a definitive answer to address this issue (particularly in the female group), the findings reduced the possibility that the observed association between the serum ACE2 level and postoperative MI following CABG was a result of ACE2 polymorphisms.

The strength of the present study was due to the use of a relatively large sample size of patients who underwent CABG and the analysis results were adjusted for multiple relevant factors, including aortic clamp time, number of grafts and pre-CABG medication use. The findings indicated that post surgery, specific attention should be given to CABG patients exhibiting a relatively low serum ACE2 level (when based on an established population-specific normal referencing range) shortly after undergoing CABG, as there is a tendency to develop postoperative MI following CABG. In addition, the findings indicate that supplementing ACE2 levels may be a potential novel therapy for postoperative MI following CABG. The limitation of the present study was that it was conducted only with patients undergoing CABG with a CPB, and patients undergoing off-pump CABG was not included. This was because CABG with a CPB was the predominant type of CABG surgery with which we were able to recruit for an adequate sample size. The association between the serum ACE2 level and postoperative MI following off-pump CABG will be investigated in future studies, based on accumulating a sample of appropriate patients.

In conclusion, the present study indicated that the serum ACE2 level 1 h post CABG was independently associated with an increased risk of postoperative MI. Thus, observations of the serum ACE2 level may be a potential novel prognostic factor for postoperative MI, following CABG.

References
1. Podgoreum MV, White WD, Morris RW, et al: Perioperative Genetics and Safety Outcomes Study (PEGASUS) Investigative Team: Inflammation and gene polymorphisms and risk of postoperative myocardial infarction after cardiac surgery. Circulation 114 (1 Suppl): I275-I281, 2006.
2. Nathoe HM, van Dijk D, Jansen EW, et al: Octopus Study Group: A comparison of on-pump and off-pump coronary bypass surgery in low-risk patients. N Engl J Med 348: 394-402, 2003.
3. Domenighetti AA, Wang Q, Egger M, Richards SM, Pedrazzini T and Delbridge LM: Angiotensin II- mediated phenotypic cardiovascular remodeling leads to age-dependent cardiac dysfunction and failure. Hypertension 46: 426-432, 2005.
4. Mazzoli L, Pedrazzini T, Nicoud F, Gabbiani G, Brunner HR and Nussberger J: Increased cardiac angiotensin II levels induce right and left ventricular hypertrophy in normotensive mice. Hypertension 35: 985-991, 2000.
5. Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Godbout K, Parsons T, Baronas E, Hsieh F, et al: Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem 277: 14838-14843, 2002.
6. Der Sarkissian S, Huentelman MJ, Stewart J, Katovich MJ and Raizada MK: ACE2: A novel therapeutic target for cardiovascular disease. Preg Biophys Mol Biol 91: 163-198, 2006.
7. Raizada MK and Ferreira AJ: ACE2: a new target for cardiovascular disease therapeutics. J Cardiovasc Pharmacol 50: 112-119, 2007.
8. Burrell LM, Risvans J, Kubota E, et al: Myocardial infarction increases ACE2 expression in rat and humans. Eur Heart J 26: 369-375; discussion 322-324, 2005.
9. Hamming I, Cooper ME, Haagmans BL, et al: The emerging role of ACE2 in physiology and disease. J Pathol 212: 1-11, 2007.
10. Der Sarkissian S, Grobe JL, Yuan L, Narelwala DR, Walter GA, Katovich MJ and Raizada MK: Cardiac overexpression of angiotensin converting enzyme 2 protects the heart from ischemia-induced pathophysiology. Hypertension 51: 712-718, 2008.
11. Zhao YX, Yin HQ, Yu QT, et al: ACE2 overexpression ameliorates left ventricular remodeling and dysfunction in a rat model of myocardial infarction. J Gene Ther 21: 1545-1554, 2010.
12. Ortiz Pérez JT, Riera M, Genover XB, De Caralt TM, et al: Serum ACE2 activity correlates with infarct size and left ventricular dysfunction during acute myocardial infarction. J Cardiovasc Magn Reson 13 (Suppl 1): P142, 2011.
13. Thysen K, Alpert JS and White HD: Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction: Universal definition of myocardial infarction. J Am Coll Cardiol 50: 2173-2195, 2007.
14. Yang W, Huang W, Su S, Li B, Zhao W, Chen S and Gu D: Association study of ACE2 (angiotensin I-converting enzyme 2) gene polymorphisms and coronary heart disease and myocardial infarction in a Chinese Han population. Clin Sci (Lond) 111: 333-340, 2006.
15. Kassiri Z, Zhong J, Guo D, et al: Loss of angiotensin-converting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarction. Circ Heart Fail 2: 446-455, 2009.
16. Keidar S, Gamlief-Lazarovich A, Kaplan M, et al: Mineralocorticoid receptor blocker increases angiotensin-converting enzyme 2 activity in congestive heart failure patients. Circ Res 97: 946-953, 2005.
17. Ferrario CM, Jessup J, Chappell MC, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 111: 2605-2610, 2005.
18. Alyanakian MA, Dehoux M, Chatel D, et al: Cardiac troponin I in diagnosis of perioperative myocardial infarction after cardiac surgery. J Cardiothorac Vasc Anesth 12: 288-294, 1998.
19. Lim CC, Cuculi F, van Gaal WJ, et al: Early diagnosis of perioperative myocardial infarction after coronary bypass grafting: a study using biomarkers and cardiac magnetic resonance imaging. Ann Thorac Surg 92: 2046-2053, 2011.
20. Burchill LJ, Velkoska E, Dean RG, Griggs K, Patel SK and Burrell LM: Combination renin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions. Clin Sci (Lond) 123:649-658, 2012.
21. Mahajan VS and Jarolim P: How to interpret elevated cardiac troponin levels. Circulation 124: 2350-2354, 2011.